Gencurix Inc.

A229000

KR7229000005

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
3,240 ^KRW	+4.52%		+2.21%	-47.91%

04-15	J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	CI
04-03	J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	CI

Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

June 07, 2021

On June 8, 2021, Gencurix Inc. (KOSDAQ:A229000) closed the transaction.

Latest news about Gencurix Inc.

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	04-14	CI
J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	04-02	CI
Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.	01-24	CI
HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc.	01-23	CI
HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc.	01-16	CI
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	12-27	CI
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	12-19	CI
Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test	14/06/23	CI
Gencurix Announces Clinical Research Results at Asco Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, Oncotypedx	07/06/23	CI
Gencurix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results	09/05/23	CI
Gencurix to Raise 28 Billion Won From Stock Offering	17/01/23	MT
Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	07/06/21	CI
Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	30/05/21	CI
Gencurix Inc. announced that it has received KRW 2 billion in funding	30/08/20	CI
Gencurix Inc. announced that it expects to receive KRW 2 billion in funding	20/08/20	CI
Gencurix Inc. agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.	20/08/20	CI
Gencurix Inc. Receives U.S. Food and Drug Administration's Emergency Use Authorization for Its GenePro SARS-CoV-2 Test	24/06/20	CI
Gencurix to Release New Coronavirus Diagnostic Kit in the EU	20/03/20	CI
Gencurix Inc. announced that it has received KRW 1.299999 billion in funding from AJU Capital Co., Ltd., Samsung Securities Co. Ltd., Investment Arm	10/02/20	CI
Gencurix Inc. announced that it expects to receive KRW 1.299999 billion in funding from AJU Capital Co., Ltd., Samsung Securities Co. Ltd., Investment Arm	09/02/20	CI
Gencurix Inc. announced that it has received KRW 4.0000215 billion in funding from Korea Investment Partners Co. Ltd., KDB Capital Corporation, Investment Arm	30/01/20	CI
Gencurix Inc. announced that it expects to receive KRW 4.0000215 billion in funding from Korea Investment Partners Co. Ltd., KDB Capital Corporation, Investment Arm	27/01/20	CI
Gencurix, Inc. Announces the First Comparison Data between GenesWell BCT and Oncotype DX	14/08/19	CI
Gencurix Announces Further Evidences for GenesWell™ BCT	06/12/18	CI

Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENCURIX INC.	-47.91%	32.78M
BIOMÉRIEUX	-4.92%	12.11B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.82%	8.07B
DIASORIN S.P.A.	+5.43%	5.67B
LANTHEUS HOLDINGS, INC.	+27.37%	5.48B
AUTOBIO DIAGNOSTICS CO., LTD.	-9.58%	4.12B
10X GENOMICS, INC.	-59.61%	2.75B
ANDON HEALTH CO., LTD.	+8.44%	2.62B
VITROLIFE AB	-3.70%	2.33B
MYRIAD GENETICS, INC.	+20.14%	2.11B